Journal
ANNALS OF ONCOLOGY
Volume 28, Issue -, Pages 30-35Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdx449
Keywords
clinical trial; consensus statement; ovarian cancer
Categories
Funding
- Astra Zeneca UK Limited (UK)
- Bristol-Myers Squibb Company (USA)
- Bristol Myers K.K. (Japan)
- Clovis Oncology Inc. (USA)
- Eisai Co., Ltd. (Japan)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Pfizer Inc. (USA)
- Pharma Mar, S.A. (Spain)
- TESARO, Inc. (USA)
- Zeria Pharmaceutical Co., Ltd. (Japan)
- Spanish Ovarian Cancer Research Group (GEICO)
- European Society for Medical Oncology (ESMO)
Ask authors/readers for more resources
The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in accordance with the mission statement to establish 'International Consensus for Designing Better Clinical Trials'. The methodology for obtaining consensus was previously established and followed during the Fifth OCCC. All 29 clinical trial groups of GCIG participated in program development and deliberations. Draft consensus statements were discussed in topic groups as well as in a plenary forum. The final statements were then presented to all 29 member groups for voting and documentation of the level of consensus. Full consensus was obtained for 11 of the 15 statements with 28/29 groups agreeing to 3 statements, and 27/29 groups agreeing to 1 statement. The high acceptance rate of the statements among trial groups reflects the fact that we share common questions, and recognise important unmet needs that will guide future research in ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available